Back to news

JAMA Study Using Alamar Biosciences’ NULISA Assay Links Blood eMTBR-tau to Tau tangle Burden in Former Football Players with Advanced CTE

Globe Newswire•20/11/2026•08:30 ET
0

Key Highlights

  • ➤Alamar’s NULISA assay linked higher blood eMTBR-tau to advanced CTE pathology
  • ➤Study included 21 former football players; 18 had CTE, including 16 high-stage cases
  • ➤eMTBR-tau levels were highest in participants with both CTE and Alzheimer’s disease
  • ➤p-tau217 tracked Alzheimer’s pathology but was not associated with CTE
  • ➤Blood test remains investigational and requires validation in larger, diverse cohorts

Expert Statements

Yuling Luo, Founder, CEO and chair of Alamar Biosciences

“CTE has been extraordinarily difficult to study because doctors cannot confirm it in a living person. Proteins like eMTBR-tau have recently been associated with neuropathology but are present at very low levels in blood”

Yuling Luo, Founder, CEO and chair of Alamar Biosciences

“Our NULISA technology was built to measure low abundant proteins, and a reliable, simple blood test for CTE would enable new research into the progression and treatment of this debilitating illness. There is more work to do, but studies like this one show why that effort matters.”

Nicholas Ashton, PhD, co-senior author of the study and senior director of Banner Health’s Fluid Biomarker Program

“Having blood tests that accurately determine the underlying pathology, which are now approved for use in Alzheimer’s disease, has been revolutionary in the way we diagnose patients and design therapeutic trials”

Nicholas Ashton, PhD, co-senior author of the study and senior director of Banner Health’s Fluid Biomarker Program

“With this new study, we are optimistic this biomarker will spur a serious discussion about treatment development for CTE.”

FREMONT, Calif., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced new research published in the Journal of the American Medical Association (JAMA). Researchers at Boston University CTE Center, with collaborators at Banner Health and more than 20 Institutions, used Alamar’s NULISAqpcr™ eMTBR-tau single-plex assay to evaluate whether a blood test could identify chronic traumatic encephalopathy (CTE) pathology in living patients.

The researchers found higher blood levels of eMTBR-tau in former football players with advanced CTE and that levels rose with the amount of tau tangle pathology in the brain. eMTBR-tau is a protein fragment linked to the tau tangles seen in CTE and Alzheimer’s disease. CTE is a. neurodegenerative disease associated with repeated head impacts. Today it can only be confirmed by examining the brain after death. The finding could give researchers a way to study CTE during life.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in